Clinical Benefits of Achieving Deep Remission to Second-Line Therapy in Patients with Relapse/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) - a Real-World Study

被引：0
|
作者：
Wierda, William G.
Gauthier, Genevieve
Meissner, Brian
Guerin, Annie
Samp, Jennifer C.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2130
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Italian Real-World Analysis of a Tyrosine Kinase Inhibitor Administration as First- or Second-Line of Therapy in Patients with Chronic Myeloid Leukemia
    Perrone, Valentina
    Giacomini, Elisa
    Andretta, Margherita
    Arenare, Loredana
    Cillo, Maria Rosaria
    Latini, Marisa
    Mecozzi, Alessandra
    Pagliaro, Romina
    Vercellone, Adriano
    Degli Esposti, Luca
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2021, 17 : 617 - 622
  • [22] TARGETED TREATMENTS FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A SYSTEMATIC LITERATURE REVIEW (SLR) OF RANDOMIZED CLINICAL TRIALS (RCTS)
    Mohseninejad, L.
    Walder, L.
    Ubi, S.
    Malyon, A.
    Yang, K.
    Olie, R.
    VALUE IN HEALTH, 2023, 26 (12) : S548 - S549
  • [23] Real-World Effectiveness and Safety Outcomes of Acalabrutinib Treatment By Line of Therapy in Patients with Chronic Lymphocytic Leukemia and/or Small Lymphocytic Lymphoma
    Jacobs, Ryan W.
    Teschemaker, Anna
    Hakre, Shweta
    Tian, Hongping
    Pyrih, Nick
    Wahlstrom, Svea K.
    Cui, Lianzhou
    BLOOD, 2023, 142
  • [24] Real-World Treatment Switching and Sequencing to Next Line of Therapy of Zanubrutinib, Acalabrutinib, and Ibrutinib in Chronic/Small Lymphocytic Leukemia (CLL/SLL)
    Pinilla-Ibarz, Javier
    Xue, Mei
    Wu, Elizabeth
    Esselman, Kaitlyn
    Furnback, Wesley
    Challagulla, Swetha
    Yang, Keri
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S358 - S359
  • [25] Second-line use of dasatinib and nilotinib in a real-world patient population with chronic phase chronic myeloid leukemia
    Toptas, Tayfur
    Demirtas, Derya
    Yanik, Ahmet Mert
    Candan, Ozlem
    Arikan, Fatma
    Salim, Secil
    Menguc, Meral
    Yilmaz, Asu Fergun
    Tuglular, Tulin
    Kaygusuz Atagunduz, Isik
    HEMATOLOGY, 2025, 30 (01)
  • [26] PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA - CLINICAL BENEFITS OF ACHIEVING A DEEP RESPONSE TO FIRST-LINE THERAPY
    Samp, J.
    Guerin, A.
    Foster, R.
    Meissner, B.
    Rokito, A.
    Enschede, S. H.
    Gauthier, G.
    HAEMATOLOGICA, 2017, 102 : 718 - 719
  • [27] CLINICAL OUTCOMES OF PATIENTS WITH RELAPSED/ REFRACTORY LARGE B-CELL LYMPHOMA RECEIVING SECOND-LINE THERAPY IN ENGLAND: A MULTICENTER, RETROSPECTIVE, REAL-WORLD STUDY
    Fox, C. P.
    Toron, F.
    Tyas, E.
    Cooper, M.
    Richards, J.
    Williams, P.
    VALUE IN HEALTH, 2023, 26 (12) : S16 - S17
  • [28] Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)
    Sun, Clare C.
    Nierman, Pia
    Ahn, Inhye E.
    Valdez, Janet
    Lotter, Jennifer
    Soto, Susan
    Herman, Sarah E. M.
    Covey, Todd
    Hamdy, Ahmed
    Izumi, Raquel
    Liu, Dongmei
    Patel, Priti
    Wiestner, Adrian
    BLOOD, 2018, 132
  • [29] Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia
    Muluneh, Benyam
    Coombs, Catherine
    Drawdy, Lauren
    Kline, Theresa
    Deal, Allison
    Zhu, Anqi
    Miller, Jordan
    Sketch, Margo
    LEUKEMIA & LYMPHOMA, 2020, 61 : 119 - 119
  • [30] Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia
    Collins, James
    Stump, Sarah E.
    Heiling, Hillary
    Muir, Michele
    Deal, Allison
    Proco, Darrian
    Nguyen, Catharine
    Cozad, Monica
    Mato, Anthony
    Coombs, Catherine C.
    Muluneh, Benyam
    LEUKEMIA & LYMPHOMA, 2022, 63 (08) : 1823 - 1830
12345